Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT03092323




Registration number
NCT03092323
Ethics application status
Date submitted
15/03/2017
Date registered
27/03/2017
Date last updated
18/11/2023

Titles & IDs
Public title
A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity
Scientific title
SU2C-SARC032: A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab With Radiotherapy and Adjuvant Pembrolizumab in Patients With High-Risk, Localized Soft Tissue Sarcoma of the Extremity
Secondary ID [1] 0 0
SU2C-SARC032
Universal Trial Number (UTN)
Trial acronym
SU2C-SARC032
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Soft Tissue Sarcoma of the Extremity 0 0
Condition category
Condition code
Cancer 0 0 0 0
Sarcoma (also see 'Bone') - soft tissue
Cancer 0 0 0 0
Bone

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Pembrolizumab

Experimental: Treatment - Neoadjuvant pembrolizumab with concurrent radiotherapy, followed by surgical resection and adjuvant pembrolizumab.

No Intervention: Standard of Care - Neoadjuvant radiotherapy followed by surgical resection.


Treatment: Drugs: Pembrolizumab
Pembrolizumab will be administered at 200 mg intravenously every 3 weeks for patients on the treatment arm.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Disease free survival
Timepoint [1] 0 0
2 Years
Secondary outcome [1] 0 0
Loco-regional disease-free survival
Timepoint [1] 0 0
5 years
Secondary outcome [2] 0 0
Distant disease free survival
Timepoint [2] 0 0
5 years
Secondary outcome [3] 0 0
Overall survival
Timepoint [3] 0 0
5 years
Secondary outcome [4] 0 0
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Timepoint [4] 0 0
5 years

Eligibility
Key inclusion criteria
- Age = 12 years

- Histologically confirmed diagnosis of grade 2 or 3 out of 3 UPS or
dedifferentiated/pleomorphic LPS of the extremity (including limb girdle, i.e.
shoulder or hip) that measures greater than 5 cm in any direction as assessed by
imaging

- Patients with non-melanomatous skin cancer, in situ carcinoma, or low-risk prostate
cancer can be enrolled.

- ECOG Performance Status of 0 or 1

- Resectable primary tumor with no evidence of metastatic disease by imaging.

- Adequate organ function within 10 days of Day 1

- Written, voluntary informed consent

- Fertile men and women of childbearing potential must agree to use an effective method
of birth control from Day 1 of study and for 120 days after last pembrolizumab
administration in both sexes. Women of childbearing potential include pre-menopausal
women and women within the first 2 years of the onset of menopause. Women of
childbearing potential must have a negative pregnancy test = 72 hours prior to Day 1
of study.
Minimum age
12 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Prior chemotherapy, targeted small molecule therapy, or radiation therapy for current
diagnosis of sarcoma

- Prior radiation therapy in excess of 20 Gy to the site of the current diagnosis of
sarcoma. No overlap with prior radiation fields in excess of 20 Gy is allowed.

- Concurrent, clinically significant, active malignancies within two years of study
enrollment.

- Patients with locally recurrent sarcoma after surgery alone are eligible for
enrollment if other inclusion criteria are met.

- Patients with severe and/or uncontrolled concurrent medical disease that in the
opinion of the investigator could cause unacceptable safety risks or compromise
compliance with the protocol

- Major surgery within four weeks prior to Day 1 of study or who have not recovered
adequately from prior surgery.

- Currently receiving a study therapy or if they had an investigational agent within 4
weeks at the time of enrollment.

- Women who are pregnant or nursing/breastfeeding, or expecting to conceive or men who
are expecting to father children within the projected duration of the trial, starting
with the pre-screening or screening visit through 120 days after the last dose of
pembrolizumab.

- Inability to comply with protocol required procedures

- Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other
form of immunosuppressive therapy by oral or IV routes within 7 days prior to the
first dose of trial treatment

- Known history of active TB (Bacillus Tuberculosis)

- Hypersensitivity to pembrolizumab or any of its excipients

- Metastatic disease or regional lymph node involvement. Chest CT will be mandatory
prior to enrollment to evaluate for the presence of metastatic disease. Pulmonary
nodule(s) < 5 mm without a histological diagnosis may not be the basis for study
exclusion given the lack of specificity of chest CT. If pulmonary nodule(s) measuring
6 - 10 mm are noted on chest CT but appear stable relative to prior chest imaging of
at least 6 months duration or if 18FDG-PET scan indicates that the nodule(s) are
unlikely to be metastatic disease, then this is permitted. Pulmonary nodules >10 mm
should be considered metastatic unless proven otherwise by biopsy/resection or stable
appearance for at least 6 months on imaging.

- Unresectable disease or medically inoperable

- Planned to receive neoadjuvant or adjuvant chemotherapy for current diagnosis of
localized soft tissue sarcoma

- Active autoimmune disease that has required systemic treatment in the past two years
(i.e. with use of disease modifying agents, systemic corticosteroids or
immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or
physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency,
etc.) is not considered a form of systemic treatment.

- Has a history of (non-infectious) pneumonitis that required systemic steroids or
current pneumonitis.

- Active infection requiring systemic therapy

- Known psychiatric or substance abuse disorders that would interfere with cooperation
with the requirements of the trial

- Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent

- Known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies)

- Known active Hepatitis B (e.g., HBsAg reactive, confirmed by detectable viral load) or
Hepatitis C (e.g., HCV RNA [qualitative] detected)

- Received a live vaccine within 30 days of planned start of study therapy. Note:
Seasonal influenza vaccines for injection are generally inactivated flu vaccines and
are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live
attenuated vaccines, and are not allowed.

- Diagnosis of scleroderma.

- Diagnosis of inflammatory bowel disease (Crohn's disease or Ulcerative Colitis).

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
19/07/2017
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/09/2028
Actual
Sample size
Target
126
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Recruitment hospital [1] 0 0
Chris O'Brien Hospital - Camperdown
Recruitment hospital [2] 0 0
Princess Alexandra Hospital - Brisbane
Recruitment hospital [3] 0 0
Peter MacCallum Cancer Centre - Melbourne
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
4102 - Brisbane
Recruitment postcode(s) [3] 0 0
3000 - Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Iowa
Country [4] 0 0
United States of America
State/province [4] 0 0
Kansas
Country [5] 0 0
United States of America
State/province [5] 0 0
Maryland
Country [6] 0 0
United States of America
State/province [6] 0 0
Massachusetts
Country [7] 0 0
United States of America
State/province [7] 0 0
Michigan
Country [8] 0 0
United States of America
State/province [8] 0 0
Missouri
Country [9] 0 0
United States of America
State/province [9] 0 0
New York
Country [10] 0 0
United States of America
State/province [10] 0 0
North Carolina
Country [11] 0 0
United States of America
State/province [11] 0 0
Ohio
Country [12] 0 0
United States of America
State/province [12] 0 0
Oregon
Country [13] 0 0
United States of America
State/province [13] 0 0
Pennsylvania
Country [14] 0 0
Canada
State/province [14] 0 0
Quebec
Country [15] 0 0
Italy
State/province [15] 0 0
MI

Funding & Sponsors
Primary sponsor type
Other
Name
Sarcoma Alliance for Research through Collaboration
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
Stand Up To Cancer
Address [1] 0 0
Country [1] 0 0
Other collaborator category [2] 0 0
Commercial sector/Industry
Name [2] 0 0
Merck Sharp & Dohme LLC
Address [2] 0 0
Country [2] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
This is an open-label, multi-institutional phase II randomized study comparing neoadjuvant
radiotherapy followed by surgical resection to neoadjuvant pembrolizumab with concurrent
radiotherapy, followed by surgical resection and adjuvant pembrolizumab. The total duration
of pembrolizumab will be one year in the experimental arm.
Trial website
https://clinicaltrials.gov/ct2/show/NCT03092323
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
David Kirsch, MD, PhD
Address 0 0
Princess Margaret Cancer Center
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT03092323